Together with Embleema we Announce Partnership to Deploy Next-Generation Real-World Data Solutions for Life Sciences

This strategic partnership brings next-generation real-world data solutions to the healthcare industry, improving patient outcomes through rich, continuous data, and regulatory-grade evidence.

News
Published on:
October 28, 2020

NEW YORK, FRAMINGHAM, MA & PARIS– Alira Health, a leading international healthcare and life sciences advisory firm, and Embleema, the innovative software provider for patient-driven healthcare data platforms, today announced a strategic partnership to develop next-generation real-world data solutions aimed at accelerating clinical innovation and improving patient outcomes.

“Our partnership with Embleema is a critical step in the further development of our real-world evidence capabilities, which connects clinical research, hospital care, and the patient experience,” says Gabriele Brambilla, Chief Executive Officer of Alira Health. Romain Finas, VP of Real World Evidence at Alira Health, adds, “We are excited to offer our clients new solutions for real-world data, which will empower them to better evaluate their treatments and deliver new innovations to patients more quickly.”

Robert Chu, Chief Executive Officer of Embleema added: “We are thrilled to take part in this strategic partnership with Alira Health, which is internationally recognized for the quality and the breadth of their service portfolio for life sciences. By teaming with Alira Health’s world-class consultants and experts, we will be able to better serve patients, regulators, and life sciences by scaling the deployment of our technology solutions.”

Embleema’s technology solutions enable the secure exchange of real-world data and the generation of regulatory-grade evidence through the HIVE big data and bioinformatics platform currently in use by the U.S. Food and Drug Administration. Alira Health’s team of biotechnicians and data generation managers use this data to design and publish clinical studies in real-life settings and create and implement tailored data platforms for clients globally, making every data point meaningful and actionable for organizations across the healthcare ecosystem.

This partnership marks an important step forward in breaking data silos with seamless end-to-end solutions that help the life sciences industry develop personalized treatments and allow hospital managers to leverage their data to improve the patient experience.

For more information, please contact Romain Finas

Click here to view the press release on Business Wire.

 

About Embleema

Embleema’s unique technology platform and expertise accelerate outcomes generation and regulatory reviews for health products. Embleema was co-founded by Robert Chu, former Senior Vice-President of Global Technology at IQVIA, Dr. Vahan Simonyan, former Director of Bioinformatics R&D and lead scientist at the U.S. Food and Drug Administration and Nicolas Schmidt, former Head of Product Development, Nokia Healthcare. Embleema provides its technology to leading life sciences regulators and companies such as the U.S. FDA and Johnson & Johnson, academia such as George Washington University and New York University Langone, and patient advocacy groups such as Multiple Sclerosis Association of America and the Epilepsy Foundation.

For more information, please visit www.embleema.com.

To read our FAQ and learn more about our partnership with Embleema:

Click here

Related news

Advanced Analytics
News December 1, 2020
We Achieved AWS Select Consulting Partner Status
We have recently earned Amazon Web Services (AWS) Select Consulting Partner status. The firm’s newly formed Advanced Analytics practice will leverage AWS’s cloud computing capabilities(...)
Advanced Analytics Regulatory Research & Development
News November 20, 2020
Alira Health’s Ventures Portfolio Company, X-COR Therapeutics, Closes Initial $2.6M Funding Round
Alira Health congratulates X-COR Therapeutics for closing a $2.6M seed financing to continue developing its novel extracorporeal carbon dioxide removal device toward clinical trials.(...)
Advanced Analytics Market Access Pharma
Publications November 1, 2020
Our Parallel Trade Expertise
Alira Health is proud to announce our new collaboration with Mark Inigo Jones, an industry leader in European parallel trade of pharmaceutical products.
Advanced Analytics
Publications October 13, 2020
Developing Learning Organizations around Health Data
Alira Health, a healthcare and life sciences consultancy with expertise in health data, approaches the development of health data in an integrated way, bringing together clinicians,(...)
Advanced Analytics
News June 15, 2020
We Announce the Acquisition of Care Factory, SAS
We have acquired Care Factory (http://www.carefactory.fr/en), a consulting firm headquartered in Paris, France, with expertise in real-world evidence based on large centralized patient(...)
Advanced Analytics Pharma
Publications June 8, 2020
Prioritization Strategy of R&D Targets for Biotech Company with Specific Platform Technology
When our client, a biotech company, wanted to understand the potential of their targets, Alira Health helped develop a web-based tool that prioritized targets and provided a decision support system.
Advanced Analytics Regulatory
Publications April 14, 2020
COVID-19: A Healthcare Stakeholders Analysis in the United States and EU-5
COVID-19: Monitoring Impacts and Anticipating Trends to Limit Downturn and Optimize Rebound

Our locations around the globe

Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.